Back to Results
First PageMeta Content
Mycology / Yeasts / Fungal diseases / Echinocandins / Pfizer / Micafungin / Candida krusei / Fungemia / Candidiasis / Biology / Antifungals / Microbiology


Rationale for the EUCAST clinical breakpoints
Add to Reading List

Document Date: 2013-02-17 05:08:52


Open Document

File Size: 170,88 KB

Share Result on Facebook

Continent

Europe / /

Facility

Hall et al. / /

MedicalCondition

liver tumour / disseminated candidiasis / invasive infection / candidiasis / neutropenia / Clinical data Invasive candidiasis / invasive candidiasis / invasive infections / infection / invasive fungal infections / infections / emergent infections / candidaemia and invasive candidiasis / oesophageal candidiasis / invasive fungal infection / /

MedicalTreatment

catheter / intravenous therapy / /

NaturalFeature

Andes / /

Organization

EUCAST MIC / European Society for Clinical Microbiology and Infectious Diseases / European Centre for Disease Prevention and Control / European Society for Clinical Microbiology / European Committee on Antimicrobial Susceptibility Testing / Infectious Diseases / /

Person

Candida spp / Micafungin spp / /

Position

General / /

Product

itraconazole / amphotericin B / fluconazole / /

Technology

Pharmacokinetics / http / transplantation / Pharmacodynamics / simulation / genotype / pdf / /

URL

http /

SocialTag